http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Tue, 02 Jun 2026 11:00:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/Zealand+Pharma+to+participate+in+the+Goldman+Sachs+Global+Healthcare+Conference/26589553.html <p>Press release – No. 12 / 2026</p> <p><b>Zealand Pharma to participate in the Goldman Sachs Global Healthcare Conference</b></p> <p><b>Copenhagen, Denmark, June 2, 2026 </b>- Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company transforming the future of metabolic health, announced that Chief Executive Officer, Adam Steensberg, will participate in a fireside chat at the Goldman Sachs 47^th Annual Global Healthcare Conference in Miami on Tuesday, June 9, 2026, at 1:20pm EDT (7:20pm CEST).</p> <p>A live audio webcast of the fireside chat will be available at <a href="https://www.globenewswire.com/Tracker?data=15-LWA71Wb0EEVF1czxuPKkc1DwNYTOnygGGzjZevaHK1lkBHBMDj6_p_E2B9Rc7tggFzAY8MTYOCoqJdRwK9Fibf4yMKcPib_9pwD-6HXV-m7ig1tMPBhYr0bLJIJUlu4p8qHQDNbLTYqoYPqz7zOe0lWGbCpKGQw-BFDXsIVCGNr4EFzjePEJRNEYBzU5ItqFffFgyKj5ObFgib5vqS8okvti0rl3KpBTejmIx9PFXvL7dAZjR5EUNpn-PxBY1K_OZv-jZ-4x8foW0t2XRZg==" rel="nofollow" target="_blank">https://event.webcasts.com/starthere.jsp?ei=1764316&amp;tp_key=1b9fe8174a&amp;language=en-us</a>, and accessible through the company’s website at http://www.streetinsider.com/Press+Releases/Zealand+Pharma+to+participate+in+the+Goldman+Sachs+Global+Healthcare+Conference/26589553.html Tue, 02 Jun 2026 11:00:00 -0400 ZEAL ZEAL http://www.streetinsider.com/Press+Releases/Zealand+Pharma+to+participate+in+the+Goldman+Sachs+Global+Healthcare+Conference/26589553.html <p>Press release – No. 12 / 2026</p> <p><b>Zealand Pharma to participate in the Goldman Sachs Global Healthcare Conference</b></p> <p><b>Copenhagen, Denmark, June 2, 2026 </b>- Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company transforming the future of metabolic health, announced that Chief Executive Officer, Adam Steensberg, will participate in a fireside chat at the Goldman Sachs 47^th Annual Global Healthcare Conference in Miami on Tuesday, June 9, 2026, at 1:20pm EDT (7:20pm CEST).</p> <p>A live audio webcast of the fireside chat will be available at <a href="https://www.globenewswire.com/Tracker?data=15-LWA71Wb0EEVF1czxuPKkc1DwNYTOnygGGzjZevaHK1lkBHBMDj6_p_E2B9Rc7tggFzAY8MTYOCoqJdRwK9Fibf4yMKcPib_9pwD-6HXV-m7ig1tMPBhYr0bLJIJUlu4p8qHQDNbLTYqoYPqz7zOe0lWGbCpKGQw-BFDXsIVCGNr4EFzjePEJRNEYBzU5ItqFffFgyKj5ObFgib5vqS8okvti0rl3KpBTejmIx9PFXvL7dAZjR5EUNpn-PxBY1K_OZv-jZ-4x8foW0t2XRZg==" rel="nofollow" target="_blank">https://event.webcasts.com/starthere.jsp?ei=1764316&amp;tp_key=1b9fe8174a&amp;language=en-us</a>, and accessible through the company’s website at http://www.streetinsider.com/Press+Releases/Zealand+Pharma+to+participate+in+the+Goldman+Sachs+Global+Healthcare+Conference/26589553.html Tue, 02 Jun 2026 11:00:00 -0400 ZEAL ZEAL http://www.streetinsider.com/Globe+Newswire/Zealand+Pharma+to+participate+in+the+Goldman+Sachs+Global+Healthcare+Conference/26589553.html <p>Press release – No. 12 / 2026</p> <p><b>Zealand Pharma to participate in the Goldman Sachs Global Healthcare Conference</b></p> <p><b>Copenhagen, Denmark, June 2, 2026 </b>- Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company transforming the future of metabolic health, announced that Chief Executive Officer, Adam Steensberg, will participate in a fireside chat at the Goldman Sachs 47^th Annual Global Healthcare Conference in Miami on Tuesday, June 9, 2026, at 1:20pm EDT (7:20pm CEST).</p> <p>A live audio webcast of the fireside chat will be available at <a href="https://www.globenewswire.com/Tracker?data=15-LWA71Wb0EEVF1czxuPKkc1DwNYTOnygGGzjZevaHK1lkBHBMDj6_p_E2B9Rc7tggFzAY8MTYOCoqJdRwK9Fibf4yMKcPib_9pwD-6HXV-m7ig1tMPBhYr0bLJIJUlu4p8qHQDNbLTYqoYPqz7zOe0lWGbCpKGQw-BFDXsIVCGNr4EFzjePEJRNEYBzU5ItqFffFgyKj5ObFgib5vqS8okvti0rl3KpBTejmIx9PFXvL7dAZjR5EUNpn-PxBY1K_OZv-jZ-4x8foW0t2XRZg==" rel="nofollow" target="_blank">https://event.webcasts.com/starthere.jsp?ei=1764316&amp;tp_key=1b9fe8174a&amp;language=en-us</a>, and accessible through the company’s website at http://www.streetinsider.com/Globe+Newswire/Zealand+Pharma+to+participate+in+the+Goldman+Sachs+Global+Healthcare+Conference/26589553.html Tue, 02 Jun 2026 11:00:00 -0400 ZEAL ZEAL http://www.streetinsider.com/Globe+Newswire/Zealand+Pharma+to+participate+in+the+Goldman+Sachs+Global+Healthcare+Conference/26589553.html <p>Press release – No. 12 / 2026</p> <p><b>Zealand Pharma to participate in the Goldman Sachs Global Healthcare Conference</b></p> <p><b>Copenhagen, Denmark, June 2, 2026 </b>- Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company transforming the future of metabolic health, announced that Chief Executive Officer, Adam Steensberg, will participate in a fireside chat at the Goldman Sachs 47^th Annual Global Healthcare Conference in Miami on Tuesday, June 9, 2026, at 1:20pm EDT (7:20pm CEST).</p> <p>A live audio webcast of the fireside chat will be available at <a href="https://www.globenewswire.com/Tracker?data=15-LWA71Wb0EEVF1czxuPKkc1DwNYTOnygGGzjZevaHK1lkBHBMDj6_p_E2B9Rc7tggFzAY8MTYOCoqJdRwK9Fibf4yMKcPib_9pwD-6HXV-m7ig1tMPBhYr0bLJIJUlu4p8qHQDNbLTYqoYPqz7zOe0lWGbCpKGQw-BFDXsIVCGNr4EFzjePEJRNEYBzU5ItqFffFgyKj5ObFgib5vqS8okvti0rl3KpBTejmIx9PFXvL7dAZjR5EUNpn-PxBY1K_OZv-jZ-4x8foW0t2XRZg==" rel="nofollow" target="_blank">https://event.webcasts.com/starthere.jsp?ei=1764316&amp;tp_key=1b9fe8174a&amp;language=en-us</a>, and accessible through the company’s website at http://www.streetinsider.com/Globe+Newswire/Zealand+Pharma+to+participate+in+the+Goldman+Sachs+Global+Healthcare+Conference/26589553.html Tue, 02 Jun 2026 11:00:00 -0400 ZEAL ZEAL http://www.streetinsider.com/Press+Releases/Zealand+Pharma+-+Transactions+related+to+share+buy-back+program+%28week+22%2C+2026%29/26581098.html <p align="justify">Company announcement No. 20 / 2026</p> <p align="justify"><b>Zealand Pharma - Transactions related to share buy-back program (week 22, 2026)</b></p> <p align="justify"><b>Copenhagen, Denmark, June 1, 2026</b> – Zealand Pharma A/S ("the Company" or “Zealand Pharma”) (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company transforming the future of metabolic health, today reports transactions related to its share buy-back program (the “Program”) for week 22 (May 26-29, 2026).</p> <p align="justify">The Program is carried out in accordance with Article 5 of Regulation (EU) No 596/2014 (the Market Abuse Regulation, “MAR”) and Commission Delegated Regulation (EU) 2016/1052 (the “Safe Harbour Regulation”). Reference http://www.streetinsider.com/Press+Releases/Zealand+Pharma+-+Transactions+related+to+share+buy-back+program+%28week+22%2C+2026%29/26581098.html Mon, 01 Jun 2026 11:00:00 -0400 ZEAL ZEAL http://www.streetinsider.com/Press+Releases/Zealand+Pharma+-+Transactions+related+to+share+buy-back+program+%28week+22%2C+2026%29/26581098.html <p align="justify">Company announcement No. 20 / 2026</p> <p align="justify"><b>Zealand Pharma - Transactions related to share buy-back program (week 22, 2026)</b></p> <p align="justify"><b>Copenhagen, Denmark, June 1, 2026</b> – Zealand Pharma A/S ("the Company" or “Zealand Pharma”) (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company transforming the future of metabolic health, today reports transactions related to its share buy-back program (the “Program”) for week 22 (May 26-29, 2026).</p> <p align="justify">The Program is carried out in accordance with Article 5 of Regulation (EU) No 596/2014 (the Market Abuse Regulation, “MAR”) and Commission Delegated Regulation (EU) 2016/1052 (the “Safe Harbour Regulation”). Reference http://www.streetinsider.com/Press+Releases/Zealand+Pharma+-+Transactions+related+to+share+buy-back+program+%28week+22%2C+2026%29/26581098.html Mon, 01 Jun 2026 11:00:00 -0400 ZEAL ZEAL http://www.streetinsider.com/Globe+Newswire/Zealand+Pharma+-+Transactions+related+to+share+buy-back+program+%28week+22%2C+2026%29/26581098.html <p align="justify">Company announcement No. 20 / 2026</p> <p align="justify"><b>Zealand Pharma - Transactions related to share buy-back program (week 22, 2026)</b></p> <p align="justify"><b>Copenhagen, Denmark, June 1, 2026</b> – Zealand Pharma A/S ("the Company" or “Zealand Pharma”) (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company transforming the future of metabolic health, today reports transactions related to its share buy-back program (the “Program”) for week 22 (May 26-29, 2026).</p> <p align="justify">The Program is carried out in accordance with Article 5 of Regulation (EU) No 596/2014 (the Market Abuse Regulation, “MAR”) and Commission Delegated Regulation (EU) 2016/1052 (the “Safe Harbour Regulation”). Reference http://www.streetinsider.com/Globe+Newswire/Zealand+Pharma+-+Transactions+related+to+share+buy-back+program+%28week+22%2C+2026%29/26581098.html Mon, 01 Jun 2026 11:00:00 -0400 ZEAL ZEAL http://www.streetinsider.com/Globe+Newswire/Zealand+Pharma+-+Transactions+related+to+share+buy-back+program+%28week+22%2C+2026%29/26581098.html <p align="justify">Company announcement No. 20 / 2026</p> <p align="justify"><b>Zealand Pharma - Transactions related to share buy-back program (week 22, 2026)</b></p> <p align="justify"><b>Copenhagen, Denmark, June 1, 2026</b> – Zealand Pharma A/S ("the Company" or “Zealand Pharma”) (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company transforming the future of metabolic health, today reports transactions related to its share buy-back program (the “Program”) for week 22 (May 26-29, 2026).</p> <p align="justify">The Program is carried out in accordance with Article 5 of Regulation (EU) No 596/2014 (the Market Abuse Regulation, “MAR”) and Commission Delegated Regulation (EU) 2016/1052 (the “Safe Harbour Regulation”). Reference http://www.streetinsider.com/Globe+Newswire/Zealand+Pharma+-+Transactions+related+to+share+buy-back+program+%28week+22%2C+2026%29/26581098.html Mon, 01 Jun 2026 11:00:00 -0400 ZEAL ZEAL http://www.streetinsider.com/Press+Releases/Transactions+in+Zealand+Pharma+shares+andor+related+securities+by+persons+discharging+managerial+responsibilities+andor+their+closely+associated+persons/26574832.html <p>Company announcement – No. 19 / 2026</p> <p><b>Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons</b></p> <p><b>Copenhagen, Denmark, May 29, 2026 </b>– Zealand Pharma A/S (&quot;the Company&quot; or “Zealand Pharma”) (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company transforming the future of metabolic health, has received information on transactions in Zealand Pharma&apos;s shares or related securities conducted by persons discharging managerial responsibilities and/or their closely associated persons and hereby publishes the information on such transactions.</p> <p>Please see the attached file(s).</p> <p><strong>About Zealand Pharma</strong></p> <p>Zealand Pharma A/S (Nasdaq: http://www.streetinsider.com/Press+Releases/Transactions+in+Zealand+Pharma+shares+andor+related+securities+by+persons+discharging+managerial+responsibilities+andor+their+closely+associated+persons/26574832.html Fri, 29 May 2026 16:00:00 -0400 O.00289404 ZEAL http://www.streetinsider.com/Press+Releases/Transactions+in+Zealand+Pharma+shares+andor+related+securities+by+persons+discharging+managerial+responsibilities+andor+their+closely+associated+persons/26574832.html <p>Company announcement – No. 19 / 2026</p> <p><b>Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons</b></p> <p><b>Copenhagen, Denmark, May 29, 2026 </b>– Zealand Pharma A/S (&quot;the Company&quot; or “Zealand Pharma”) (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company transforming the future of metabolic health, has received information on transactions in Zealand Pharma&apos;s shares or related securities conducted by persons discharging managerial responsibilities and/or their closely associated persons and hereby publishes the information on such transactions.</p> <p>Please see the attached file(s).</p> <p><strong>About Zealand Pharma</strong></p> <p>Zealand Pharma A/S (Nasdaq: http://www.streetinsider.com/Press+Releases/Transactions+in+Zealand+Pharma+shares+andor+related+securities+by+persons+discharging+managerial+responsibilities+andor+their+closely+associated+persons/26574832.html Fri, 29 May 2026 16:00:00 -0400 O.00289404 ZEAL http://www.streetinsider.com/Globe+Newswire/Transactions+in+Zealand+Pharma+shares+andor+related+securities+by+persons+discharging+managerial+responsibilities+andor+their+closely+associated+persons/26574832.html <p>Company announcement – No. 19 / 2026</p> <p><b>Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons</b></p> <p><b>Copenhagen, Denmark, May 29, 2026 </b>– Zealand Pharma A/S (&quot;the Company&quot; or “Zealand Pharma”) (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company transforming the future of metabolic health, has received information on transactions in Zealand Pharma&apos;s shares or related securities conducted by persons discharging managerial responsibilities and/or their closely associated persons and hereby publishes the information on such transactions.</p> <p>Please see the attached file(s).</p> <p><strong>About Zealand Pharma</strong></p> <p>Zealand Pharma A/S (Nasdaq: http://www.streetinsider.com/Globe+Newswire/Transactions+in+Zealand+Pharma+shares+andor+related+securities+by+persons+discharging+managerial+responsibilities+andor+their+closely+associated+persons/26574832.html Fri, 29 May 2026 16:00:00 -0400 O.00289404 ZEAL http://www.streetinsider.com/Globe+Newswire/Transactions+in+Zealand+Pharma+shares+andor+related+securities+by+persons+discharging+managerial+responsibilities+andor+their+closely+associated+persons/26574832.html <p>Company announcement – No. 19 / 2026</p> <p><b>Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons</b></p> <p><b>Copenhagen, Denmark, May 29, 2026 </b>– Zealand Pharma A/S (&quot;the Company&quot; or “Zealand Pharma”) (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company transforming the future of metabolic health, has received information on transactions in Zealand Pharma&apos;s shares or related securities conducted by persons discharging managerial responsibilities and/or their closely associated persons and hereby publishes the information on such transactions.</p> <p>Please see the attached file(s).</p> <p><strong>About Zealand Pharma</strong></p> <p>Zealand Pharma A/S (Nasdaq: http://www.streetinsider.com/Globe+Newswire/Transactions+in+Zealand+Pharma+shares+andor+related+securities+by+persons+discharging+managerial+responsibilities+andor+their+closely+associated+persons/26574832.html Fri, 29 May 2026 16:00:00 -0400 O.00289404 ZEAL http://www.streetinsider.com/Press+Releases/Zealand+Pharma+to+participate+in+the+Jefferies+Global+Healthcare+Conference/26555503.html <p>Press release – No. 11 / 2026</p> <p><b>Zealand Pharma to participate in the Jefferies Global Healthcare Conference</b></p> <p><b>Copenhagen, Denmark, May 27, 2026 </b>- Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company transforming the future of metabolic health, announced that Chief Financial Officer, Henriette Wennicke, and Chief Scientific Officer, Utpal Singh, will participate in a fireside chat at the Jefferies Global Healthcare Conference in New York on Wednesday, June 3, 2026, at 12:45pm EDT (7:45pm CEST).</p> <p>A live audio webcast of the fireside chat will be available at <a href="https://www.globenewswire.com/Tracker?data=uUuzKGRKK758fQaWyTVEfLAsuEVZdbv8wel71DErzldsq1vsbDRLoqpWZfdw1a9cVIVRrrugarhV4HVNfEG2ap7uPXBJ-lIcrSi1HDzT6qXOBvofO8nwlk4pFSO4W5S646ZzKm8KX_Njb-wbg7tP4C-fEkJRdV3X__Vz2YIYjH2hAyQRbHKpPCA-ljhy2qVmQ62xt60LzPptotr5KQhXppdAjxL9wLsddOt9GggWRDLDdejN-Od9EuyhoQGz5MR7oZpQS5sEhX1JkFRjzLLnYlfIXPIyN1CJEyK1HfzWZrCB1S6pSfCdtthB7LuEfl1S" rel="nofollow" target="_blank">https://event.summitcast.com/view/NgCqua4VVQjq9ibVWHVWca/guest_book?session_id=neMJD52ZimWD5Fa274J7iC</a>, and accessible through the http://www.streetinsider.com/Press+Releases/Zealand+Pharma+to+participate+in+the+Jefferies+Global+Healthcare+Conference/26555503.html Wed, 27 May 2026 11:00:00 -0400 ZEAL ZEAL http://www.streetinsider.com/Press+Releases/Zealand+Pharma+to+participate+in+the+Jefferies+Global+Healthcare+Conference/26555503.html <p>Press release – No. 11 / 2026</p> <p><b>Zealand Pharma to participate in the Jefferies Global Healthcare Conference</b></p> <p><b>Copenhagen, Denmark, May 27, 2026 </b>- Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company transforming the future of metabolic health, announced that Chief Financial Officer, Henriette Wennicke, and Chief Scientific Officer, Utpal Singh, will participate in a fireside chat at the Jefferies Global Healthcare Conference in New York on Wednesday, June 3, 2026, at 12:45pm EDT (7:45pm CEST).</p> <p>A live audio webcast of the fireside chat will be available at <a href="https://www.globenewswire.com/Tracker?data=uUuzKGRKK758fQaWyTVEfLAsuEVZdbv8wel71DErzldsq1vsbDRLoqpWZfdw1a9cVIVRrrugarhV4HVNfEG2ap7uPXBJ-lIcrSi1HDzT6qXOBvofO8nwlk4pFSO4W5S646ZzKm8KX_Njb-wbg7tP4C-fEkJRdV3X__Vz2YIYjH2hAyQRbHKpPCA-ljhy2qVmQ62xt60LzPptotr5KQhXppdAjxL9wLsddOt9GggWRDLDdejN-Od9EuyhoQGz5MR7oZpQS5sEhX1JkFRjzLLnYlfIXPIyN1CJEyK1HfzWZrCB1S6pSfCdtthB7LuEfl1S" rel="nofollow" target="_blank">https://event.summitcast.com/view/NgCqua4VVQjq9ibVWHVWca/guest_book?session_id=neMJD52ZimWD5Fa274J7iC</a>, and accessible through the http://www.streetinsider.com/Press+Releases/Zealand+Pharma+to+participate+in+the+Jefferies+Global+Healthcare+Conference/26555503.html Wed, 27 May 2026 11:00:00 -0400 ZEAL ZEAL http://www.streetinsider.com/Globe+Newswire/Zealand+Pharma+to+participate+in+the+Jefferies+Global+Healthcare+Conference/26555503.html <p>Press release – No. 11 / 2026</p> <p><b>Zealand Pharma to participate in the Jefferies Global Healthcare Conference</b></p> <p><b>Copenhagen, Denmark, May 27, 2026 </b>- Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company transforming the future of metabolic health, announced that Chief Financial Officer, Henriette Wennicke, and Chief Scientific Officer, Utpal Singh, will participate in a fireside chat at the Jefferies Global Healthcare Conference in New York on Wednesday, June 3, 2026, at 12:45pm EDT (7:45pm CEST).</p> <p>A live audio webcast of the fireside chat will be available at <a href="https://www.globenewswire.com/Tracker?data=uUuzKGRKK758fQaWyTVEfLAsuEVZdbv8wel71DErzldsq1vsbDRLoqpWZfdw1a9cVIVRrrugarhV4HVNfEG2ap7uPXBJ-lIcrSi1HDzT6qXOBvofO8nwlk4pFSO4W5S646ZzKm8KX_Njb-wbg7tP4C-fEkJRdV3X__Vz2YIYjH2hAyQRbHKpPCA-ljhy2qVmQ62xt60LzPptotr5KQhXppdAjxL9wLsddOt9GggWRDLDdejN-Od9EuyhoQGz5MR7oZpQS5sEhX1JkFRjzLLnYlfIXPIyN1CJEyK1HfzWZrCB1S6pSfCdtthB7LuEfl1S" rel="nofollow" target="_blank">https://event.summitcast.com/view/NgCqua4VVQjq9ibVWHVWca/guest_book?session_id=neMJD52ZimWD5Fa274J7iC</a>, and accessible through the http://www.streetinsider.com/Globe+Newswire/Zealand+Pharma+to+participate+in+the+Jefferies+Global+Healthcare+Conference/26555503.html Wed, 27 May 2026 11:00:00 -0400 ZEAL ZEAL http://www.streetinsider.com/Globe+Newswire/Zealand+Pharma+to+participate+in+the+Jefferies+Global+Healthcare+Conference/26555503.html <p>Press release – No. 11 / 2026</p> <p><b>Zealand Pharma to participate in the Jefferies Global Healthcare Conference</b></p> <p><b>Copenhagen, Denmark, May 27, 2026 </b>- Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company transforming the future of metabolic health, announced that Chief Financial Officer, Henriette Wennicke, and Chief Scientific Officer, Utpal Singh, will participate in a fireside chat at the Jefferies Global Healthcare Conference in New York on Wednesday, June 3, 2026, at 12:45pm EDT (7:45pm CEST).</p> <p>A live audio webcast of the fireside chat will be available at <a href="https://www.globenewswire.com/Tracker?data=uUuzKGRKK758fQaWyTVEfLAsuEVZdbv8wel71DErzldsq1vsbDRLoqpWZfdw1a9cVIVRrrugarhV4HVNfEG2ap7uPXBJ-lIcrSi1HDzT6qXOBvofO8nwlk4pFSO4W5S646ZzKm8KX_Njb-wbg7tP4C-fEkJRdV3X__Vz2YIYjH2hAyQRbHKpPCA-ljhy2qVmQ62xt60LzPptotr5KQhXppdAjxL9wLsddOt9GggWRDLDdejN-Od9EuyhoQGz5MR7oZpQS5sEhX1JkFRjzLLnYlfIXPIyN1CJEyK1HfzWZrCB1S6pSfCdtthB7LuEfl1S" rel="nofollow" target="_blank">https://event.summitcast.com/view/NgCqua4VVQjq9ibVWHVWca/guest_book?session_id=neMJD52ZimWD5Fa274J7iC</a>, and accessible through the http://www.streetinsider.com/Globe+Newswire/Zealand+Pharma+to+participate+in+the+Jefferies+Global+Healthcare+Conference/26555503.html Wed, 27 May 2026 11:00:00 -0400 ZEAL ZEAL http://www.streetinsider.com/Press+Releases/Zealand+Pharma+to+Present+Data+at+the+American+Diabetes+Association%27s+2026+Scientific+Sessions/26552361.html <p>Press release – No. 10 / 2026</p> <p align="center"><b>Zealand Pharma to Present Data at</b><br /><b>the American Diabetes Association's 2026 Scientific Sessions</b></p> <p align="center"><i>Late-breaking Phase 2 ZUPREME-1 data on petrelintide to be featured as ePoster Theater presentation and poster sessions</i></p> <p><b>Copenhagen, Denmark, May 27, 2026 </b>– Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company transforming the future of metabolic health, today announced that data from its obesity and metabolic health pipeline will be presented at <a href="https://www.globenewswire.com/Tracker?data=FemN-3L_Bf-xPJf5xag8ymkdxqMUsBIcoEaNv7JwLL2X-i1x4rilmA-zdQf-cFihQXiRNrx-u21jCyceCTantJC7CTJ8dDbVaZ8M__Ggaw5KUtMC5gcwKbtXcESvEfASA55rNlVXhTCUEztGziPe0MdJTita66SHmsyblhjT30RrtNrRpvEuY11oInBi4Z7zYGBr5oPuQNc57bFvG80m7g==" rel="nofollow" target="_blank">the 2026 Scientific Sessions of the American Diabetes Association® (ADA)</a> taking place June 5–8, 2026, at the Ernest N. http://www.streetinsider.com/Press+Releases/Zealand+Pharma+to+Present+Data+at+the+American+Diabetes+Association%27s+2026+Scientific+Sessions/26552361.html Wed, 27 May 2026 03:00:00 -0400 ZEAL ZEAL http://www.streetinsider.com/Press+Releases/Zealand+Pharma+to+Present+Data+at+the+American+Diabetes+Association%27s+2026+Scientific+Sessions/26552361.html <p>Press release – No. 10 / 2026</p> <p align="center"><b>Zealand Pharma to Present Data at</b><br /><b>the American Diabetes Association's 2026 Scientific Sessions</b></p> <p align="center"><i>Late-breaking Phase 2 ZUPREME-1 data on petrelintide to be featured as ePoster Theater presentation and poster sessions</i></p> <p><b>Copenhagen, Denmark, May 27, 2026 </b>– Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company transforming the future of metabolic health, today announced that data from its obesity and metabolic health pipeline will be presented at <a href="https://www.globenewswire.com/Tracker?data=FemN-3L_Bf-xPJf5xag8ymkdxqMUsBIcoEaNv7JwLL2X-i1x4rilmA-zdQf-cFihQXiRNrx-u21jCyceCTantJC7CTJ8dDbVaZ8M__Ggaw5KUtMC5gcwKbtXcESvEfASA55rNlVXhTCUEztGziPe0MdJTita66SHmsyblhjT30RrtNrRpvEuY11oInBi4Z7zYGBr5oPuQNc57bFvG80m7g==" rel="nofollow" target="_blank">the 2026 Scientific Sessions of the American Diabetes Association® (ADA)</a> taking place June 5–8, 2026, at the Ernest N. http://www.streetinsider.com/Press+Releases/Zealand+Pharma+to+Present+Data+at+the+American+Diabetes+Association%27s+2026+Scientific+Sessions/26552361.html Wed, 27 May 2026 03:00:00 -0400 ZEAL ZEAL http://www.streetinsider.com/Globe+Newswire/Zealand+Pharma+to+Present+Data+at+the+American+Diabetes+Association%27s+2026+Scientific+Sessions/26552361.html <p>Press release – No. 10 / 2026</p> <p align="center"><b>Zealand Pharma to Present Data at</b><br /><b>the American Diabetes Association's 2026 Scientific Sessions</b></p> <p align="center"><i>Late-breaking Phase 2 ZUPREME-1 data on petrelintide to be featured as ePoster Theater presentation and poster sessions</i></p> <p><b>Copenhagen, Denmark, May 27, 2026 </b>– Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company transforming the future of metabolic health, today announced that data from its obesity and metabolic health pipeline will be presented at <a href="https://www.globenewswire.com/Tracker?data=FemN-3L_Bf-xPJf5xag8ymkdxqMUsBIcoEaNv7JwLL2X-i1x4rilmA-zdQf-cFihQXiRNrx-u21jCyceCTantJC7CTJ8dDbVaZ8M__Ggaw5KUtMC5gcwKbtXcESvEfASA55rNlVXhTCUEztGziPe0MdJTita66SHmsyblhjT30RrtNrRpvEuY11oInBi4Z7zYGBr5oPuQNc57bFvG80m7g==" rel="nofollow" target="_blank">the 2026 Scientific Sessions of the American Diabetes Association® (ADA)</a> taking place June 5–8, 2026, at the Ernest N. http://www.streetinsider.com/Globe+Newswire/Zealand+Pharma+to+Present+Data+at+the+American+Diabetes+Association%27s+2026+Scientific+Sessions/26552361.html Wed, 27 May 2026 03:00:00 -0400 ZEAL ZEAL http://www.streetinsider.com/Globe+Newswire/Zealand+Pharma+to+Present+Data+at+the+American+Diabetes+Association%27s+2026+Scientific+Sessions/26552361.html <p>Press release – No. 10 / 2026</p> <p align="center"><b>Zealand Pharma to Present Data at</b><br /><b>the American Diabetes Association's 2026 Scientific Sessions</b></p> <p align="center"><i>Late-breaking Phase 2 ZUPREME-1 data on petrelintide to be featured as ePoster Theater presentation and poster sessions</i></p> <p><b>Copenhagen, Denmark, May 27, 2026 </b>– Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company transforming the future of metabolic health, today announced that data from its obesity and metabolic health pipeline will be presented at <a href="https://www.globenewswire.com/Tracker?data=FemN-3L_Bf-xPJf5xag8ymkdxqMUsBIcoEaNv7JwLL2X-i1x4rilmA-zdQf-cFihQXiRNrx-u21jCyceCTantJC7CTJ8dDbVaZ8M__Ggaw5KUtMC5gcwKbtXcESvEfASA55rNlVXhTCUEztGziPe0MdJTita66SHmsyblhjT30RrtNrRpvEuY11oInBi4Z7zYGBr5oPuQNc57bFvG80m7g==" rel="nofollow" target="_blank">the 2026 Scientific Sessions of the American Diabetes Association® (ADA)</a> taking place June 5–8, 2026, at the Ernest N. http://www.streetinsider.com/Globe+Newswire/Zealand+Pharma+to+Present+Data+at+the+American+Diabetes+Association%27s+2026+Scientific+Sessions/26552361.html Wed, 27 May 2026 03:00:00 -0400 ZEAL ZEAL http://www.streetinsider.com/Press+Releases/Zealand+Pharma+to+Present+Data+at+the+American+Diabetes+Association%26apos%3Bs+2026+Scientific+Sessions/26552363.html <p>Press release – No. 10 / 2026</p> <p align="center"><b>Zealand Pharma to Present Data at</b><br/><b>the American Diabetes Association&apos;s 2026 Scientific Sessions</b></p> <p align="center"><i>Late-breaking Phase 2 ZUPREME-1 data on petrelintide to be featured as ePoster Theater presentation and poster sessions</i></p> <p><b>Copenhagen, Denmark, May 27, 2026 </b>– Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company transforming the future of metabolic health, today announced that data from its obesity and metabolic health pipeline will be presented at <a target="_blank" href="https://www.globenewswire.com/Tracker?data=FemN-3L_Bf-xPJf5xag8ymkdxqMUsBIcoEaNv7JwLL2X-i1x4rilmA-zdQf-cFihQXiRNrx-u21jCyceCTantJC7CTJ8dDbVaZ8M__Ggaw5KUtMC5gcwKbtXcESvEfASA55rNlVXhTCUEztGziPe0MdJTita66SHmsyblhjT30RrtNrRpvEuY11oInBi4Z7zYGBr5oPuQNc57bFvG80m7g==" rel="nofollow" target="_blank">the 2026 Scientific Sessions of the American Diabetes Association® (ADA)</a> taking place June 5–8, 2026, at the Ernest N. http://www.streetinsider.com/Press+Releases/Zealand+Pharma+to+Present+Data+at+the+American+Diabetes+Association%26apos%3Bs+2026+Scientific+Sessions/26552363.html Wed, 27 May 2026 03:00:00 -0400 A.20822773 O.00289404 O.20370956 ZEAL http://www.streetinsider.com/Press+Releases/Zealand+Pharma+to+Present+Data+at+the+American+Diabetes+Association%26apos%3Bs+2026+Scientific+Sessions/26552363.html <p>Press release – No. 10 / 2026</p> <p align="center"><b>Zealand Pharma to Present Data at</b><br/><b>the American Diabetes Association&apos;s 2026 Scientific Sessions</b></p> <p align="center"><i>Late-breaking Phase 2 ZUPREME-1 data on petrelintide to be featured as ePoster Theater presentation and poster sessions</i></p> <p><b>Copenhagen, Denmark, May 27, 2026 </b>– Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company transforming the future of metabolic health, today announced that data from its obesity and metabolic health pipeline will be presented at <a target="_blank" href="https://www.globenewswire.com/Tracker?data=FemN-3L_Bf-xPJf5xag8ymkdxqMUsBIcoEaNv7JwLL2X-i1x4rilmA-zdQf-cFihQXiRNrx-u21jCyceCTantJC7CTJ8dDbVaZ8M__Ggaw5KUtMC5gcwKbtXcESvEfASA55rNlVXhTCUEztGziPe0MdJTita66SHmsyblhjT30RrtNrRpvEuY11oInBi4Z7zYGBr5oPuQNc57bFvG80m7g==" rel="nofollow" target="_blank">the 2026 Scientific Sessions of the American Diabetes Association® (ADA)</a> taking place June 5–8, 2026, at the Ernest N. http://www.streetinsider.com/Press+Releases/Zealand+Pharma+to+Present+Data+at+the+American+Diabetes+Association%26apos%3Bs+2026+Scientific+Sessions/26552363.html Wed, 27 May 2026 03:00:00 -0400 A.20822773 O.00289404 O.20370956 ZEAL http://www.streetinsider.com/Press+Releases/Zealand+Pharma+to+Present+Data+at+the+American+Diabetes+Association%26apos%3Bs+2026+Scientific+Sessions/26552363.html <p>Press release – No. 10 / 2026</p> <p align="center"><b>Zealand Pharma to Present Data at</b><br/><b>the American Diabetes Association&apos;s 2026 Scientific Sessions</b></p> <p align="center"><i>Late-breaking Phase 2 ZUPREME-1 data on petrelintide to be featured as ePoster Theater presentation and poster sessions</i></p> <p><b>Copenhagen, Denmark, May 27, 2026 </b>– Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company transforming the future of metabolic health, today announced that data from its obesity and metabolic health pipeline will be presented at <a target="_blank" href="https://www.globenewswire.com/Tracker?data=FemN-3L_Bf-xPJf5xag8ymkdxqMUsBIcoEaNv7JwLL2X-i1x4rilmA-zdQf-cFihQXiRNrx-u21jCyceCTantJC7CTJ8dDbVaZ8M__Ggaw5KUtMC5gcwKbtXcESvEfASA55rNlVXhTCUEztGziPe0MdJTita66SHmsyblhjT30RrtNrRpvEuY11oInBi4Z7zYGBr5oPuQNc57bFvG80m7g==" rel="nofollow" target="_blank">the 2026 Scientific Sessions of the American Diabetes Association® (ADA)</a> taking place June 5–8, 2026, at the Ernest N. http://www.streetinsider.com/Press+Releases/Zealand+Pharma+to+Present+Data+at+the+American+Diabetes+Association%26apos%3Bs+2026+Scientific+Sessions/26552363.html Wed, 27 May 2026 03:00:00 -0400 A.20822773 O.00289404 O.20370956 ZEAL http://www.streetinsider.com/Press+Releases/Zealand+Pharma+to+Present+Data+at+the+American+Diabetes+Association%26apos%3Bs+2026+Scientific+Sessions/26552363.html <p>Press release – No. 10 / 2026</p> <p align="center"><b>Zealand Pharma to Present Data at</b><br/><b>the American Diabetes Association&apos;s 2026 Scientific Sessions</b></p> <p align="center"><i>Late-breaking Phase 2 ZUPREME-1 data on petrelintide to be featured as ePoster Theater presentation and poster sessions</i></p> <p><b>Copenhagen, Denmark, May 27, 2026 </b>– Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company transforming the future of metabolic health, today announced that data from its obesity and metabolic health pipeline will be presented at <a target="_blank" href="https://www.globenewswire.com/Tracker?data=FemN-3L_Bf-xPJf5xag8ymkdxqMUsBIcoEaNv7JwLL2X-i1x4rilmA-zdQf-cFihQXiRNrx-u21jCyceCTantJC7CTJ8dDbVaZ8M__Ggaw5KUtMC5gcwKbtXcESvEfASA55rNlVXhTCUEztGziPe0MdJTita66SHmsyblhjT30RrtNrRpvEuY11oInBi4Z7zYGBr5oPuQNc57bFvG80m7g==" rel="nofollow" target="_blank">the 2026 Scientific Sessions of the American Diabetes Association® (ADA)</a> taking place June 5–8, 2026, at the Ernest N. http://www.streetinsider.com/Press+Releases/Zealand+Pharma+to+Present+Data+at+the+American+Diabetes+Association%26apos%3Bs+2026+Scientific+Sessions/26552363.html Wed, 27 May 2026 03:00:00 -0400 A.20822773 O.00289404 O.20370956 ZEAL http://www.streetinsider.com/Globe+Newswire/Zealand+Pharma+to+Present+Data+at+the+American+Diabetes+Association%26apos%3Bs+2026+Scientific+Sessions/26552363.html <p>Press release – No. 10 / 2026</p> <p align="center"><b>Zealand Pharma to Present Data at</b><br/><b>the American Diabetes Association&apos;s 2026 Scientific Sessions</b></p> <p align="center"><i>Late-breaking Phase 2 ZUPREME-1 data on petrelintide to be featured as ePoster Theater presentation and poster sessions</i></p> <p><b>Copenhagen, Denmark, May 27, 2026 </b>– Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company transforming the future of metabolic health, today announced that data from its obesity and metabolic health pipeline will be presented at <a target="_blank" href="https://www.globenewswire.com/Tracker?data=FemN-3L_Bf-xPJf5xag8ymkdxqMUsBIcoEaNv7JwLL2X-i1x4rilmA-zdQf-cFihQXiRNrx-u21jCyceCTantJC7CTJ8dDbVaZ8M__Ggaw5KUtMC5gcwKbtXcESvEfASA55rNlVXhTCUEztGziPe0MdJTita66SHmsyblhjT30RrtNrRpvEuY11oInBi4Z7zYGBr5oPuQNc57bFvG80m7g==" rel="nofollow" target="_blank">the 2026 Scientific Sessions of the American Diabetes Association® (ADA)</a> taking place June 5–8, 2026, at the Ernest N. http://www.streetinsider.com/Globe+Newswire/Zealand+Pharma+to+Present+Data+at+the+American+Diabetes+Association%26apos%3Bs+2026+Scientific+Sessions/26552363.html Wed, 27 May 2026 03:00:00 -0400 A.20822773 O.00289404 O.20370956 ZEAL